SurVaxM Expanded Access Protocol

Summary

Data from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with recurrent or newly diagnosed glioblastoma, is generally well tolerated and may increase progression free survival and overall survival in some patients

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications